Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 13Endometrial Neoplasms 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms 4Neoplasms 3Uterine Neoplasms 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Prostatic Neoplasms 2Lung Neoplasms 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Melanoma 1Laryngeal Neoplasms 1Kenny-Caffey syndrome, Type 1 1Hyperglycemia 1High Grade Serous Ovarian Cancer 1Head and Neck Neoplasms 1Genital Neoplasms, Female 1Genital Diseases, Female 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 6apatinib 4camrelizumab 3S 1 (combination) 2Capecitabine 2130-nm albumin-bound paclitaxel 2vorolanib 1titanium silicide 1spartalizumab 1raltitrexed 1olaparib 1lobaplatin 1durvalumab 1Ramucirumab 1Oxaliplatin 1Gastrectomy 1Docetaxel 1Control Groups 1Cisplatin 1CF regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced Gastric Cancer × olaparib × Clear all
NCT03579784 2024-04-19

Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer

Seoul National University Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡